Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Myeloma: Update Bulletin #2 [December 2018]

Product Code:
596201022
Publication Date:
December 2018
Format:
PDF
Price:
$1,315

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the multiple myeloma (MM) market. Topics covered include: Genmab announcing results from the Phase III MAIA study comparing Darzalex (daratumumab; Genmab/Janssen Biotech) in combination with Revlimid (lenalidomide; Celgene) and dexamethasone (DRd), with Revlimid/dexamethasone; Celgene announcing results from the Phase II/III ECOG E3A06 study assessing the effect of Revlimid in patients with smoldering multiple myeloma (SMM) compared with observation alone; bluebird bio/Celgene’s release of new Phase I data fortheir CAR-T therapy bb21217 in relapsed/refractory multiple myeloma (rrMM).

Business Questions:

• How do KOLs view the topline results from the MAIA study for patients with newly-diagnosed MM who are ineligible for high-dose chemotherapy or autologous stem cell transplant (ASCT)?
• In light of its ability to prolong progression-free survival, how readily, and to what extent, is DRd likely to be adopted as a first-line therapy for MM?
• Is Darzalex in combination with Velcade (bortezomib; Takeda/Janssen),melphalan and prednisonelikely to prove a serious competitor to DRd in the treatment of newly-diagnosed patients with MM?
• On the basis of the ECOG E3A06 trial results, will KOLs be persuaded to switch from the current standard of not treating asymptomatic patients with SMM, to using Revlimid?
• Are the results of the ECOG E3A06 trial adequate for securing regulatory approval of Revlimid as a treatment for patients with SMM?
• Does the BCMA-targeting CAR-T cell therapy bb21217 represent a viable approach for treating MM?
• Do KOLs foresee any disadvantages to the use of bb21217?
• If approved, what sort of role do KOLs envisage for bb21217 within the MM treatment algorithm, and is this likely to change in the longer term?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved